Evidence map›Paper›PMID 29594732›Full record

ArticleNeurochemical research2018

Lycium barbarum Polysaccharide Promotes Nigrostriatal Dopamine Function by Modulating PTEN/AKT/mTOR Pathway in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Murine Model of Parkinson's Disease.

Xiaohong Wang, Lei Pang, Yanqing Zhang, Jiang Xu, Dongyi Ding, Tianli Yang, Qian Zhao, Fan Wu, Fei Li, Haiwei Meng and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Regulatory effects ofFrontiers in immunology · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. SNHG1 promotes MPPBiological research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaohong WangSchool of Medicine, Yangzhou University, Yangzhou, China.
Lei PangSchool of Medicine, Yangzhou University, Yangzhou, China.
Yanqing ZhangSchool of Medicine, Yangzhou University, Yangzhou, China.
Jiang XuSchool of Medicine, Yangzhou University, Yangzhou, China.
Dongyi DingSchool of Medicine, Yangzhou University, Yangzhou, China.
Tianli YangSchool of Medicine, Yangzhou University, Yangzhou, China.
Qian ZhaoSchool of Medicine, Yangzhou University, Yangzhou, China.
Fan WuSchool of Medicine, Yangzhou University, Yangzhou, China.
Fei LiSchool of Medicine, Yangzhou University, Yangzhou, China.
Haiwei MengResearch Center for Sectional and Imaging Anatomy, Shandong University School of Medicine, Jinan, 250012, China. hwmeng@sdu.edu.cn.
Duonan YuSchool of Medicine, Yangzhou University, Yangzhou, China. dnyu@yzu.edu.cn.
Yangzhou University · CNShandong University · CN

Funding

National Natural Science Foundation of China 81501135Natural science fund for colleges and universities in Jiangsu Province 15KJB310026The science and technology projects fund of Yangzhou City YZ2015112
6 · The paper itself

Abstract

To investigate the effects of Lycium barbarum polysaccharide (LBP) on pathological symptoms and behavioral deficits in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) mouse model. The therapeutic effects of LBP were monitored with an Open field test, a Rotarod test and a Morris water maze test. We also investigated the mechanisms with qRT-PCR and Western blotting analyses. After a relatively short-term LBP treatment, the total distance and walking time of PD mice significantly increased. The staying duration on the rod of PD mice increased in the Rotarod test. LBP can up-regulate levels of SOD2, CAT and GPX1 and inhibit the abnormal aggregation of α-synuclein induced by MPTP. LBP treatment can also up-regulate the phosphorylation of AKT and mTOR, and may play its protective role by activating the PTEN/AKT/mTOR signaling axis. These results suggest that LBP can effectively alleviate the degeneration in the nigrostriatal system induced by MPTP treatment. It may be a potential candidate for the treatment of Parkinson's disease.

Indexed as

AnimalsCorpus StriatumDopamineDrugs, Chinese HerbalMaleMiceMice, Inbred C57BLParkinsonian DisordersProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSignal TransductionSubstantia NigraTOR Serine-Threonine KinasesDopamineDrugs, Chinese Herballycium barbarum polysaccharidemTOR protein, mouseProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, mouseTOR Serine-Threonine KinasesLycium barbarum polysaccharideOxidative stressParkinson’s diseasePTEN/AKT/mTOR pathwayα-Synuclein

Identifiers

PMID29594732
OpenAlexW2794815065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.